COVID-19 drug trial halted early: aprepitant shows no clear benefit
NCT ID NCT04470622
First seen Mar 09, 2026 · Last updated May 14, 2026 · Updated 10 times
Summary
This study tested whether the drug aprepitant could help hospitalized COVID-19 patients recover faster. The trial was stopped early after enrolling only 27 people. Researchers aimed to see if the drug reduced the need for breathing support or shortened hospital stays.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID - 19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Helen Keller Hospital
Sheffield, Alabama, 35660, United States
-
University of California, Irvine Medical Center
Orange, California, 92868, United States
-
Yale University School of Medicine
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.